Table 1 Baseline characteristics of the 70 HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy
Characteristics | All patients (n = 70) |
|---|---|
Gender | |
Male, n (%) | 66, (94.3) |
Female, n (%) | 4, (5.7) |
Age (y)Δ | 52.5 ± 12.2 |
BCLC stage | |
B, n (%) | 18, (25.7) |
C, n (%) | 52, (74.3) |
Child–Pugh class | |
A, n (%) | 55, (78.6) |
B, n (%) | 15, (21.4) |
ECOG performance | |
0, n (%) | 50, (71.4) |
1, n (%) | 19, (27.1) |
2, n (%) | 1, (1.4) |
Portal vein tumor thrombus | |
Yes, n (%) | 42, (60.0) |
No, n (%) | 28, (40.0) |
Extrahepatic metastasis | |
Yes, n (%) | 25, (35.7) |
No, n (%) | 45, (64.3) |
Tumor number | |
< 3, n (%) | 24, (34.3) |
≥ 3, n (%) | 46, (65.7) |
Largest tumor diameter | |
< 7 cm, n (%) | 37, (52.9) |
≥ 7 cm, n (%) | 33, (47.1) |
α-Fetoprotein level | |
< 400 ng/mL, n (%) | 40, (57.1) |
≥ 400 ng/mL, n (%) | 30, (42.9) |
Antiangiogenic drug | |
Lenvatinib, n (%) | 41, (58.6) |
Sorafenib, n (%) | 8, (11.4) |
Apatinib, n (%) | 5, (7.2) |
Regorafenib, n (%) | 8, (11.4) |
Bevacizumab, n (%) | 8, (11.4) |
ALT (U/L)* | 31.5 (9.0, 146.0) |
AST (U/L)* | 46.0 (14.0, 225.0) |
Albumin (g/L)Δ | 36.7 ± 4.7 |
Total bilirubin (mmol/L)* | 15.2 (5.2, 55.8) |
PLT (109/L)* | 151.5 (34.0, 695.0) |
PT (s)Δ | 11.7 ± 1.3 |
HBV DNA | |
≤ 2000 IU/mL, n (%) | 48, (68.6) |
> 2000 IU/mL, n (%) | 22, (31.4) |
HBsAg (IU/mL)* | 403.9 (0.1, 7026.0) |
HBeAg | |
Positive, n (%) | 9, (12.9) |
Negative, n (%) | 61, (87.1) |